WallStreetZenWallStreetZen

NYSEMKT: ATNM
Actinium Pharmaceuticals Inc Stock Forecast, Predictions & Price Target

OverviewForecast
EarningsRevenueDividendOwnership

Analyst price target for ATNM

Based on 1 analyst offering 12 month price targets for Actinium Pharmaceuticals Inc

Min Forecast
$4.00+175.86%
Avg Forecast
$4.00+175.86%
Max Forecast
$4.00+175.86%

Should I buy or sell ATNM stock?

Based on 1 analyst offering ratings for Actinium Pharmaceuticals Inc.

Buy
Strong Buy
0 analysts 0%
Buy
1 analysts 100%
Hold
0 analysts 0%
Sell
0 analysts 0%
Strong Sell
0 analysts 0%

Be the first to know when Wall Street analysts revise their ATNM stock forecasts and price targets.

ATNM stock forecasts by analyst

Analyst / FirmRatingActionPrice TargetUpside/DownsideDateAnalyst Color
lockedlocked$00.00+00.00%2025-06-24

1 of 1

Forecast return on equity

Is ATNM forecast to generate an efficient return?

Company
-140.82%
Industry
254.98%
Market
226.6%
ATNM's Return on Equity is... subscribe to Premium to read more.
Forecast High Return on Equity Forecast

Forecast return on assets

Is ATNM forecast to generate an efficient return on assets?

Company
-34.57%
Industry
90.68%
ATNM is forecast to generate... subscribe to Premium to read more.
Forecast Return on Assets vs Industry Forecast

ATNM earnings per share forecast

What is ATNM's earnings per share in the next 3 years based on estimates from 7 analysts?

Avg 1 year Forecast
-$1.10
Avg 2 year Forecast
-$0.81
Avg 3 year Forecast
-$1.01

ATNM revenue forecast

What is ATNM's revenue in the next 3 years based on estimates from 7 analysts?

Avg 1 year Forecast
$45.9k-49%
Avg 2 year Forecast
$19.8M+21,852.22%
Avg 3 year Forecast
$47.5M+52,726.67%
ATNM's revenue is forecast to... subscribe to Premium to read more.
Forecast High Revenue Growth Forecast

ATNM revenue growth forecast

How is ATNM forecast to perform vs Biotechnology companies and vs the US market?

Company
700.49%
Industry
101.87%
Market
25.74%
ATNM's revenues are forecast to... subscribe to Premium to read more.
Forecast Revenue Growth vs Industry Forecast
ATNM's revenues are forecast to... subscribe to Premium to read more.
Forecast Revenue Growth vs Market Forecast

ATNM vs Biotech Stocks

TickerPricePrice TargetUp/downsideConsensus
ATNM$1.45$4.00+175.86%Buy
BTAI$2.07$26.67+1,188.26%Buy
CVM$6.48N/AN/A
BCAB$0.78N/AN/A
KZR$6.30$6.00-4.76%Hold
View Top Biotech Stocks

Actinium Pharmaceuticals Stock Forecast FAQ

Is Actinium Pharmaceuticals Stock a good buy in 2025, according to Wall Street analysts?

The consensus among 1 Wall Street analyst covering (NYSEMKT: ATNM) stock is to Buy ATNM stock.

Out of 1 analyst, 0 (0%) are recommending ATNM as a Strong Buy, 1 (100%) are recommending ATNM as a Buy, 0 (0%) are recommending ATNM as a Hold, 0 (0%) are recommending ATNM as a Sell, and 0 (0%) are recommending ATNM as a Strong Sell.

If you're new to stock investing, here's how to buy Actinium Pharmaceuticals stock.

What is ATNM's earnings growth forecast for 2025-2027?

(NYSEMKT: ATNM) Actinium Pharmaceuticals's forecast annual earnings growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast earnings growth rate of 44.21%, and while it is not forecast to beat the US market's average forecast earnings growth rate of 42.48%.

Actinium Pharmaceuticals's earnings in 2025 is -$34,599,000.On average, 7 Wall Street analysts forecast ATNM's earnings for 2025 to be -$34,365,394, with the lowest ATNM earnings forecast at -$33,323,451, and the highest ATNM earnings forecast at -$35,048,584. On average, 6 Wall Street analysts forecast ATNM's earnings for 2026 to be -$25,296,748, with the lowest ATNM earnings forecast at -$25,680,457, and the highest ATNM earnings forecast at -$24,566,764.

In 2027, ATNM is forecast to generate -$31,660,710 in earnings, with the lowest earnings forecast at -$35,157,769 and the highest earnings forecast at -$27,514,776.

What is ATNM's revenue growth forecast for 2025-2027?

(NYSEMKT: ATNM) Actinium Pharmaceuticals's forecast annual revenue growth rate of 700.49% is forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 101.87%, and it is also forecast to beat the US market's average forecast revenue growth rate of 25.74%.

Actinium Pharmaceuticals's revenue in 2025 is $90,000.On average, 7 Wall Street analysts forecast ATNM's revenue for 2025 to be $1,431,891, with the lowest ATNM revenue forecast at $0, and the highest ATNM revenue forecast at $2,948,012. On average, 6 Wall Street analysts forecast ATNM's revenue for 2026 to be $616,337,218, with the lowest ATNM revenue forecast at $0, and the highest ATNM revenue forecast at $1,268,924,062.

In 2027, ATNM is forecast to generate $1,483,177,442 in revenue, with the lowest revenue forecast at $1,425,028,301 and the highest revenue forecast at $1,526,820,493.

What is ATNM's forecast return on assets (ROA) for 2025-2028?

(NYSEMKT: ATNM) forecast ROA is -34.57%, which is lower than the forecast US Biotechnology industry average of 90.68%.

What is ATNM's Price Target?

According to 1 Wall Street analyst that have issued a 1 year ATNM price target, the average ATNM price target is $4.00, with the highest ATNM stock price forecast at $4.00 and the lowest ATNM stock price forecast at $4.00.

The Wall Street analyst predicted that Actinium Pharmaceuticals's share price could reach $4.00 by Jun 24, 2026. The average Actinium Pharmaceuticals stock price prediction forecasts a potential upside of 175.86% from the current ATNM share price of $1.45.

What is ATNM's Earnings Per Share (EPS) forecast for 2025-2027?

(NYSEMKT: ATNM) Actinium Pharmaceuticals's current Earnings Per Share (EPS) is -$1.10. On average, analysts forecast that ATNM's EPS will be -$1.10 for 2025, with the lowest EPS forecast at -$1.07, and the highest EPS forecast at -$1.12. On average, analysts forecast that ATNM's EPS will be -$0.81 for 2026, with the lowest EPS forecast at -$0.82, and the highest EPS forecast at -$0.79. In 2027, ATNM's EPS is forecast to hit -$1.01 (min: -$1.13, max: -$0.88).

What is ATNM's forecast return on equity (ROE) for 2025-2028?

(NYSEMKT: ATNM) forecast ROE is -140.82%, which is considered weak.
©2025 WallStreetZen
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletter
Stock Tools
Top Performing AnalystsStock ScreenerStock ForecastTrending StocksStrong Buy StocksHighest Earnings StocksBest Dividend Paying StocksStatisticsStock Market SectorsStock Market IndustriesHow to Buy Stocks Online
Stock Ideas
Buy The DipBiggest Stock Gainers TodayBiggest Stock Losers Today52 Week High Stocks52 Week Low StocksMost Active Stocks TodayMost Undervalued StocksBest Penny Stocks to Buy NowBest Stocks Under $5Best Stocks Under $10
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.